Reineke A Schoot1, Olga Slater2, Cécile M Ronckers1, Aeilko H Zwinderman3, Alfons J M Balm4, Benjamin Hartley5, Michiel W van den Brekel4, Sanjeev Gupta5, Peerooz Saeed6, Eva Gajdosova7, Bradley R Pieters8, Mark N Gaze9, Henry C Mandeville10, Raquel Davila Fajardo8, Yen Ch'ing Chang9, Jennifer E Gains9, Simon D Strackee11, David Dunaway12, Christopher Abela12, Carol Mason13, Ludi E Smeele4, Julia C Chisholm14, Gill A Levitt2, Leontien C M Kremer1, Martha A Grootenhuis15, Heleen Maurice-Stam15, Charles A Stiller16, Peter Hammond17, Huib N Caron1, Johannes H M Merks18. 1. Department of Paediatric Oncology, Emma Children's Hospital, Academic Medical Centre, Amsterdam, The Netherlands. 2. Department of Paediatric Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom. 3. Department of Clinical Epidemiology and Bio-Statistics, Academic Medical Centre, Amsterdam, The Netherlands. 4. Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Oral and Maxillofacial surgery, Academic Medical Centre, Amsterdam, The Netherlands. 5. Department of Otorhinolaryngology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom. 6. Orbital centre, Department of Ophthalmology, Academic Medical Centre, Amsterdam, The Netherlands. 7. Department of Ophthalmology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom. 8. Department of Radiation Oncology, Academic Medical Centre, Amsterdam, The Netherlands. 9. Department of Oncology, University College London Hospitals NHS Foundation Trust, London, United Kingdom. 10. Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. 11. Department of Plastic, Reconstructive and Hand Surgery, Academic Medical Centre, Amsterdam, The Netherlands. 12. Craniofacial Unit, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom. 13. Dental and Maxillofacial department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom. 14. Children and Young People's Department, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. 15. Paediatric Psychosocial Department, Emma Children's Hospital, Academic Medical Centre, Amsterdam, The Netherlands. 16. The Childhood Cancer Research Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom. 17. Molecular Medicine Unit, UCL Institute of Child Health, London, United Kingdom. 18. Department of Paediatric Oncology, Emma Children's Hospital, Academic Medical Centre, Amsterdam, The Netherlands. Electronic address: j.h.merks@amc.uva.nl.
Abstract
BACKGROUND: Radiotherapy is a well-known cause of adverse events (AEs). To reduce AEs, an innovative local treatment was developed in Amsterdam: Ablative surgery, MOuld brachytherapy and surgical REconstruction (AMORE). AIMS: (1) to determine the prevalence of AEs in HNRMS survivors and (2) to compare AEs between survivors treated with the international standard: external beam radiotherapy (EBRT-based: London) and survivors treated with AMORE if feasible, otherwise EBRT (AMORE-based: Amsterdam). METHODS: All HNRMS survivors, treated in London or Amsterdam between January 1990 and December 2010 (n = 153), and alive ⩾ 2 years post-treatment were eligible (n = 113). A predefined list of AEs was assessed in a multidisciplinary clinic and graded according to the Common Terminology Criteria for Adverse Events. RESULTS: Eighty HNRMS survivors attended the clinic (median follow-up 10.5 years); 63% experienced ⩾ 1 severe or disabling event, and 76% had ⩾ 5 AEs (any grade). Survivors with EBRT-based treatment were, after adjustment for site, age at diagnosis, and follow-up duration, at increased risk to develop any grade 3/4 event or ⩾ 5 AEs (any grade) compared with survivors with AMORE-based treatments (p = 0.032 and 0.01, respectively). Five year overall survival (source population) after EBRT-based treatment was 75.0%, after AMORE-based treatment 76.9%, p = 0.56. CONCLUSION: This study may serve as a baseline inventory and can be used in future studies for prospective assessments of AEs following the introduction of novel local treatment modalities. AMORE-based local treatment resulted in similar overall survival and a reduction of AEs secondary to local treatment.
BACKGROUND: Radiotherapy is a well-known cause of adverse events (AEs). To reduce AEs, an innovative local treatment was developed in Amsterdam: Ablative surgery, MOuld brachytherapy and surgical REconstruction (AMORE). AIMS: (1) to determine the prevalence of AEs in HNRMS survivors and (2) to compare AEs between survivors treated with the international standard: external beam radiotherapy (EBRT-based: London) and survivors treated with AMORE if feasible, otherwise EBRT (AMORE-based: Amsterdam). METHODS: All HNRMS survivors, treated in London or Amsterdam between January 1990 and December 2010 (n = 153), and alive ⩾ 2 years post-treatment were eligible (n = 113). A predefined list of AEs was assessed in a multidisciplinary clinic and graded according to the Common Terminology Criteria for Adverse Events. RESULTS: Eighty HNRMS survivors attended the clinic (median follow-up 10.5 years); 63% experienced ⩾ 1 severe or disabling event, and 76% had ⩾ 5 AEs (any grade). Survivors with EBRT-based treatment were, after adjustment for site, age at diagnosis, and follow-up duration, at increased risk to develop any grade 3/4 event or ⩾ 5 AEs (any grade) compared with survivors with AMORE-based treatments (p = 0.032 and 0.01, respectively). Five year overall survival (source population) after EBRT-based treatment was 75.0%, after AMORE-based treatment 76.9%, p = 0.56. CONCLUSION: This study may serve as a baseline inventory and can be used in future studies for prospective assessments of AEs following the introduction of novel local treatment modalities. AMORE-based local treatment resulted in similar overall survival and a reduction of AEs secondary to local treatment.
Authors: Martin T King; Laszlo Voros; Gil'ad N Cohen; Ryan M Lanning; Ian Ganly; Chibuzo C O'Suoji; Suzanne L Wolden Journal: Brachytherapy Date: 2016-08-12 Impact factor: 2.362
Authors: Joseph Lopez; Nancy Qin; Robbie Woods; Marjorie Golden; Harrison Spatz; Jatin Shah; Leonard H Wexler; Joseph Randazzo; Suzanne L Wolden; David H Abramson Journal: Plast Reconstr Surg Glob Open Date: 2022-10-07
Authors: Reinier C Hoogeveen; Marinka L F Hol; Bradley R Pieters; Brian V Balgobind; Erwin W E R Berkhout; Reineke A Schoot; Ludi E Smeele; Hans J H M Merks; Eddy A G Becking Journal: Dentomaxillofac Radiol Date: 2019-11-18 Impact factor: 2.419